About APIM Therapeutics
APIM Therapeutics is a company based in Trondheim (Norway) founded in 2009.. APIM Therapeutics has raised $3.56 million across 5 funding rounds from investors including Berg Capital Group, Investinor and Sarsia Seed. The company has 1 employees as of December 31, 2021. APIM Therapeutics offers products and services including ATX-101 and Peptide Drugs Pipeline. APIM Therapeutics operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Candel Therapeutics, among others.
- Headquarter Trondheim, Norway
- Employees 1 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Apim Therapeutics As
-
Annual Revenue
$10.86 K (USD)0as on Dec 31, 2022
-
Net Profit
$-2.75 M (USD)-78as on Dec 31, 2022
-
EBITDA
$-2.75 M (USD)-78as on Dec 31, 2022
-
Total Equity Funding
$3.56 M (USD)
in 5 rounds
-
Latest Funding Round
-
Investors
Berg Capital Group
& 4 more
-
Employee Count
1
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of APIM Therapeutics
APIM Therapeutics offers a comprehensive portfolio of products and services, including ATX-101 and Peptide Drugs Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Peptide drug targeting stress responses in cancer cells for treatment.
Pipeline of drugs addressing cancer stress responses in clinical settings.
Unlock access to complete
Unlock access to complete
Board Team
6 people
Leadership Team
2 people
Finance and Accounting
1 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of APIM Therapeutics
APIM Therapeutics has successfully raised a total of $3.56M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Last Round
-
First Round
First Round
(20 May 2010)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Series A - APIM Therapeutics | Valuation |
investors |
|
| Dec, 2017 | Amount | Series A - APIM Therapeutics | Valuation | Sarsia Seed | |
| Oct, 2012 | Amount | Series A - APIM Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in APIM Therapeutics
APIM Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Berg Capital Group, Investinor and Sarsia Seed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by APIM Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - APIM Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Apim Therapeutics Comparisons
Competitors of APIM Therapeutics
APIM Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Candel Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Apim Therapeutics
Frequently Asked Questions about APIM Therapeutics
When was APIM Therapeutics founded?
APIM Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Where is APIM Therapeutics located?
APIM Therapeutics is headquartered in Trondheim, Norway. It is registered at Trondheim, Trøndelag, Norway.
Is APIM Therapeutics a funded company?
APIM Therapeutics is a funded company, having raised a total of $3.56M across 5 funding rounds to date.
How many employees does APIM Therapeutics have?
As of Dec 31, 2021, the latest employee count at APIM Therapeutics is 1.
What is the annual revenue of APIM Therapeutics?
Annual revenue of APIM Therapeutics is $10.86K as on Dec 31, 2022.
What does APIM Therapeutics do?
APIM Therapeutics was founded in 2009 in Trondheim, Norway, within the biotechnology sector. Anti-cancer therapies are developed to potentiate chemotherapy-induced responses in cancer cells through a pipeline of peptide drugs. These target PCNA-dependent stress responses, with PCNA serving as a regulator of DNA replication, repair, and cell cycle control. The flagship candidate, ATX-101, has demonstrated proof-of-concept in animal models for blood and solid tumors.
Who are the top competitors of APIM Therapeutics?
APIM Therapeutics's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
What products or services does APIM Therapeutics offer?
APIM Therapeutics offers ATX-101 and Peptide Drugs Pipeline.
Who are APIM Therapeutics's investors?
APIM Therapeutics has 5 investors. Key investors include Berg Capital Group, Investinor, Sarsia Seed, Televenture, and Birk Venture.